ArticleNature2020
Repeat expansions confer WRN dependence in microsatellite-unstable cancers.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers.
0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed
14.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 192 citations in OpenAlex.
- CRISPR Screening Identifies SMARCAL1 and MRN as Modulators of WRN Dependency in MSI-H Colorectal Cancer.Cancer research · 2026Article
- Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release.Cancer research · 2026Article
- Article
- Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.Nature medicine · 2026Article
- A synthetic lethal drug for microsatellite instability cancers.Nature medicine · 2026Article
- Replication stress in cancer: origins, consequences and therapeutic opportunities.Nature reviews. Cancer · 2026Review
- DNA binding contributes to dominant-negative effects of a catalytically inactive RecQ4-family helicase.Nucleic acids research · 2026Article
- Suppression of transcription-replication conflicts by sequence-coordinated actions of TRDMT1 and MutLα.Nature communications · 2026Article
- Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors.Molecular cancer therapeutics · 2026Article
- Multiomic characterization of DNA released after airway exposure to allergens and nanoparticles reveals selective export of repetitive and fragile site DNA.Physiological genomics · 2026Article
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- Using cancer profiles to identify synthetic lethal therapeutic targets and predictive biomarkers in cancer gene dependency data.Bioinformatics (Oxford, England) · 2026Article
- A recurrent sequencing artifact on Illumina sequencers with two-color fluorescent dye chemistry and its impact on somatic variant detection.Genome biology · 2026Article
- RPA hyperphosphorylation hinders the resolution of R-loops and G-quadruplex-associated R-loops during RAS-driven senescence.Nucleic acids research · 2026Article
- dMMR killer: A conditional suicide gene that preferentially kills DNA mismatch repair-deficient cells.Molecular therapy. Nucleic acids · 2026Article
- Cruciform-forming AT/TA repeats are acted upon by structure-selective endonucleases and Rad51 prior to repositioning to the nuclear periphery for repair.Nucleic acids research · 2026Article
- Synthetic lethality in cancer drug discovery: challenges and opportunities.Nature reviews. Drug discovery · 2026Review
- Pan-Cancer Analysis of WRN: From Multi-Omics Biomarker Discovery to Therapy-Guiding Functional Evidence.OncoTargets and therapy · 2026Article
- Reference-Free Microsatellite Instability Detection from Tumor Sequencing Using Intrasample Variability Modeling.Computational and structural biotechnology journal · 2026Article
- Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers.Journal of medicinal chemistry · 2025Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 10 institutions in 2 countries.
Niek van Wietmarschen *Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-6136-5757
Sriram Sridharan *Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
William J Nathan *Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Anthony Tubbs *Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Edmond M Chan *Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7460-2560
Elsa CallenLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Wei WuLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Frida BelinkyLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Veenu TripathiLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Nancy WongLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Kyla FosterBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Javad NoorbakhshBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Kiran GarimellaBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Abimael Cruz-MigoniDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.ORCID http://orcid.org/0000-0001-5937-4101
Joshua A SommersLaboratory of Molecular Gerontology, National Institute on Aging, NIH, Baltimore, MD, USA.
Yongqing HuangBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Ashir A BorahBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Jonathan T SmithBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Jeremie KalfonBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Nikolas KestenCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Cambridge, MA, USA.
Kasper FuggerDNA Recombination and Repair Laboratory, The Francis Crick Institute, London, UK.
Robert L WalkerGenetics Branch, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-8235-4686
Egor DolzhenkoIllumina Inc., San Diego, CA, USA.
Michael A EberleIllumina Inc., San Diego, CA, USA.ORCID http://orcid.org/0000-0001-8965-1253
Bruce E HaywardLaboratory of Cell and Molecular Biology, National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.
Karen UsdinLaboratory of Cell and Molecular Biology, National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.
Catherine H FreudenreichDepartment of Biology, Tufts University, Medford, MA, USA.ORCID http://orcid.org/0000-0002-1652-2917
Robert M BroshLaboratory of Molecular Gerontology, National Institute on Aging, NIH, Baltimore, MD, USA.
Stephen C WestDNA Recombination and Repair Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-8848-9418
Peter J McHughDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.ORCID http://orcid.org/0000-0002-8679-4627
Paul S MeltzerGenetics Branch, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-0963-1768
Adam J BassDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8193-4758
André NussenzweigLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA. andre_nussenzweig@nih.gov.ORCID http://orcid.org/0000-0002-8952-7268
Broad Institute · USNational Human Genome Research Institute · USJohn Radcliffe Hospital · GBIllumina (United States) · USNational Cancer Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNational Institute on Aging · USThe Francis Crick Institute · GBDana-Farber Cancer Institute · USTufts University · US
Funding
Relationship between DNA damage detection and signalingZIABC010959 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NUSSENZWEIG, ANDRE A. · 2009 to 2025
$27.0MFork Restart at Replication Barriers and Effects on Genome StabilityR01GM122880 · NIGMS · TUFTS UNIVERSITY MEDFORD · PI FREUDENREICH, CATHERINE H · 2017 to 2020
$1.4MCancer Research UK 11582European Research CouncilIntramural NIH HHS ZIA BC010959Medical Research Council MR/R009368/1NIGMS NIH HHS R01 GM122880Wellcome TrustWellcome Trust MR/R009368/1
Abstract
The RecQ DNA helicase WRN is a synthetic lethal target for cancer cells with microsatellite instability (MSI), a form of genetic hypermutability that arises from impaired mismatch repair
Indexed as
DNA Breaks, Double-StrandedAtaxia Telangiectasia Mutated ProteinsCell Line, TumorChromosomes, HumanChromothripsisDinucleotide RepeatsDNA-Binding ProteinsDNA CleavageDNA Repeat ExpansionDNA ReplicationEndodeoxyribonucleasesEndonucleasesGenomic InstabilityHumansNeoplasmsRecombinasesAtaxia Telangiectasia Mutated ProteinsATR protein, humanDNA-Binding ProteinsEme1 protein, humanEndodeoxyribonucleasesEndonucleasesMUS81 protein, humanRecombinasesSLX4 protein, humanWerner Syndrome HelicaseWRN protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.